BioStock publishes interview with Monivent’s incoming CEO Tobias Tullberg

BioStock has published an interview with Tobias Tullberg ahead of his upcoming appointment as the new CEO of Monivent AB. To read the interview, please follow the links below.

Swedish: https://biostock.se/2026/09/tilltradande-vd-om-hur-monivent-ska-vaxa-i-nasta-fas/

English: https://biostock.se/en/2026/09/incoming-ceo-on-how-monivent-will-grow-in-its-next-phase/

For more information, please contact:
Maria Lindqvist, CEO
Phone: +46 70 748 01 30
E-mail: maria@monivent.se
Web: www.monivent.se

Monivent AB (”Monivent”) develops, manufactures and sells medical devices in order to improve the emergency care provided to newborns in need of respiratory support at birth. About three to six percent of all newborns end up in this critical situation and healthcare professionals today lack good tools to determine how effective this manual ventilation is. Monivent has developed equipment that measure the airflow to the child directly in the face mask via a sensor module that sends data wirelessly to an external monitor. The caregiver thereby receives immediate feedback, which enables necessary adjustments to support an effective but at the same time gentle treatment. The company is also marketing a product for simulation-based training on manikins, building on the same technology as the clinical product.